On the other hand, the tumors with positive HER2 amplification but with low or negative HER2

expression do not respond well to Trastuzumab. Therfore, immunohistochemistry is recommended to be used as the initial testing methodology, and FISH or silver in situ hybridization used to retest immunohistochemistry 2+ cases (62). Dihydropyrimidine dehydrogenase Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in uracil catabolism, and is also the main enzyme involved in the degradation of structurally related compounds like 5-Fluorouracil (5-FU), a widely used drug in treating different Inhibitors,research,lifescience,medical Inhibitors,research,lifescience,medical kinds of tumor including gastric carcinoma. True deficiency of DPD affects approximately 5% of the overall population (63).

Patients with DPD deficiency are at significantly www.selleckchem.com/products/S31-201.html increased risk of developing severe and potentially fatal neutropenia, mucositis and diarrhea (63-65) when treated with 5-FU or capecitabine. In Inhibitors,research,lifescience,medical addition, 3% to 5% of the population has a partial DPD deficiency due to sequence variations in DPYD gene, which potentially limits their ability to fully metabolize the drug, thereby resulting in toxicity (66-68). Many studies have addressed and identified the mutations of DPYD and epigenetic alterations of DPYD as the causes of lower levels Inhibitors,research,lifescience,medical of DPD or DPD deficiency. Subsequently, different tests have been developed in order to identify the people at risk of DPD deficiency, in the hope that the test results could eventually provide clinical guidance. One of the tests to identify the people Inhibitors,research,lifescience,medical with DPD deficiency is DPYD genotyping to detect the important mutations such as DPYD 2A (or IVS14+1 G>A) (66,69). While the individuals with positive DPYD mutation

have an increased risk for DPD deficiency, DPD deficiency is also noted in the people with wild type PDYD, because epigenetic alteration, such as methylation at the regulatory region of PDYP promoter can cause lower DPD level without the mutation at DNA level (70). To make issue not more complicated is that the uracil catabolic pathway involves several other enzymes such as dihydropyrimidinase (DHP) (71) and beta-urreidopropionase (BUP1) (72,73). The mutations of those genes which are at the downstream of DPD also impair uracil catabolism. Therefore, uracil breath test which involves DPD, DHP, and DUP1 may reveal more clinical information of potential toxicity in the patients who receive 5-FU treatment (74), because it evaluates the integrity of the entire catabolic pathway of uracil which cannot be archived by PDYD genotyping alone.